Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Yum China Holdings Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $514 (market cap $127.55B), while Yum China Holdings Inc trades at $42.95 (market cap $14.11B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 9× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays a 2.78% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Yum China Holdings Inc for 77 Days on average.
| VRTX | YUMC | |
|---|---|---|
Market Cap | $127.55B | $14.11B |
Volume | 1,487,944 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $557.96 | $57.95 |
52-Week Low | $407.37 | $39.98 |
Typical Hold Time | 120 Days | 77 Days |
Enterprise Value | $121.68B | $15.02B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
YUMC trades at $40.65 with minimal daily movement (+0.07%). The stock shows strong fundamental performance with consistent earnings beats (Q4 2025-Q2 2026) and solid profitability metrics (ROE 17.5%, net margin 7.84%). Recent business developments include the acquisition of Pizza Hut brand ownership in mainland China and expansion of Pizza Hut Burger Bar to 300 locations. Technical indicators show bearish momentum with the stock trading near key support at $40.
YUMC presents a compelling value opportunity with reasonable valuation multiples (P/E 15.3, P/S 1.2) and strong analyst support (73.68% buy ratings). Upside potential exists from continued store expansion and brand innovation, though investors should monitor China's consumer spending trends and competitive pressures in the restaurant sector. The stock's current technical weakness may offer entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
